DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l4nbmv/alpha6_beta4) has announced the addition of the "Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2014" report to their offering.
The Alpha6 Beta4 Integrin signaling pathway activates the PI 3-kinase/Akt, MAPK/NFkB and SMAD signaling modules.
There are today 239 companies plus partners developing 366 Alpha6 Beta4 integrin pathway targeting drugs in 1258 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 164 drugs.
Alpha6 Beta4 Integrin Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 158 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date, 156 out of the 157 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
All drugs targets are further categorized on in the software application by 35 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Investigators
- Includes more than 239 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Drug name & Synonyms
- Lists commercial, generic and code names for drugs.
Developmental stage
- This Drug Pipeline Update contains 366 Alpha6 Beta4 integrin pathway targeting drugs in development, which have a total of 1258 developmental projects in cancer. In addition there are suspended and ceased drugs.
Indications
- Included Alpha6 Beta4 integrin pathway targeting drugs are also in development for 151 other indications, where of 111 are different cancer indications.
Pipeline Breakdown According to Number of Drugs
- Marketed # 32
- Registered # 1
- Pre-registration # 5
- Phase III # 35
- Phase II # 117
- Phase I # 161
- Preclinical # 192
- No Data # 3
- Suspended # 2
- Ceased # 164
For more information visit http://www.researchandmarkets.com/research/l4nbmv/alpha6_beta4
